PFAS Exposure Lines Up With Lower Bone Density at the Adolescent Growth Spurt
Persistent exposure to PFAS during childhood and early adolescence tracked with lower bone mineral density in the HOME Study, a cohort built to capture how environmental chemicals intersect with skeletal development during a biologically sensitive window. The finding matters because bone mass accrual is not evenly distributed across childhood; it accelerates as puberty approaches, and disruptions during that interval can carry forward into adult fracture risk. In this work, higher serum PFOA concentrations stood out as the most consistent signal, with lower BMD Z-scores at the distal radius. Other PFAS showed more variable associations depending on the timing of measurement, skeletal site, and sex.
The biological logic is straightforward even when the epidemiology is not. PFAS are long-lived compounds, with human half-lives measured in years, and they have been detected in bone tissue. If they push mesenchymal stem cells away from osteogenic pathways and toward adipogenic fate through mechanisms involving PPAR-γ, then the skeleton may be losing ground precisely when it should be building reserve. Adolescence is when that reserve is stockpiled. A chemical exposure that blunts mineral accrual during that interval can leave a smaller margin for the decades that follow.
A Cohort Positioned to Catch a Developmental Effect
Jessie P. Buckley, PhD, and colleagues drew on the Health Outcomes and Measures of the Environment cohort, a prospective pregnancy and birth study that began enrolling participants between March 2003 and January 2006. For this analysis, 218 offspring were eligible because PFAS had been measured in serum at delivery and again at ages 3, 8, and 12 years, and each had a dual-energy x-ray absorptiometry scan at age 12. The exposure panel included four widely persistent compounds: PFHxS, PFOS, PFOA, and PFNA. The study design allowed investigators to ask a sharper question than many cross-sectional reports can handle: whether later childhood and early adolescent exposure coincided with stronger skeletal effects than exposures measured earlier in life.
It did. In this cohort, age 12 sat at the front edge of the rapid bone-building period, and the associations seen there were not isolated to a single scan. Preliminary age-18 repeat DXA findings showed a similar pattern, which strengthens the concern that the signal reflects a real developmental vulnerability rather than a one-off measurement artifact. The radius findings were especially important because peripheral skeletal sites can reveal changes in mineral accrual that may be less obvious at central sites. Sex- and site-specific differences also suggest that hormone status and skeletal timing may shape how these exposures translate into measurable bone deficits.
A single metric did not tell the whole story.
Why Timing During Growth May Matter More Than Cumulative Exposure Alone
The timing of exposure appears to be doing part of the explanatory work. Buckley’s group was testing whether PFAS measured at ages 8 and 12 would show stronger relationships with lower bone density than earlier measurements, on the premise that the pubertal window is a period of intense skeletal remodeling. That hypothesis fits with basic endocrine biology. Bone mineral accrual depends on coordinated hormonal signals, adequate nutrition, mechanical loading, and normal maturation of osteoblast and osteoclast activity. A persistent chemical with endocrine activity can distort that choreography without producing an immediately visible clinical syndrome.
The measured associations do not prove a direct causal chain, but they do fit a developmental toxicology model in which exposures during key windows become embedded in later structure and function. Childhood is not simply a smaller version of adulthood. It is a period in which organ systems are still deciding how much reserve to build, and environmental interference can leave a permanent mark. If PFAS exposure is present while peak bone mass is being laid down, the effect may show up years later as less robust skeletal reserve, even before frank osteoporosis becomes a clinical concern.
Diet, Activity, and Exposure Control Offer Two Different Levers
Buckley also placed the cohort findings in a practical frame. One lever is reducing PFAS exposure at the population level, since many sources are difficult for individuals to avoid. The other is less glamorous but immediately actionable: diet and physical activity may buffer some of the skeletal association. In a separate study she cited, the link between PFAS and lower BMD was evident among adolescents with lower calcium intake and physical activity, but not among those with more optimal habits. That pattern does not erase the exposure risk; it suggests a partial biological offset through stronger bone loading and better mineral supply.
For clinicians, the message is not to reduce bone health to a single lab value or a single exposure history. A child with low bone density may have nutritional, mechanical, hormonal, genetic, and environmental contributors operating at once. Environmental history deserves a place in that differential, especially in patients with suspected high exposure or unexplained skeletal findings. The growing attention to PFAS testing and clinical follow-up, including National Academies guidance, reflects that shift toward a broader diagnostic lens.
Why This Cohort Adds Weight to the Pediatric Endocrine Debate
This study carries unusual value because the participants have been followed since childhood, and the cohort has remained engaged long enough to make late adolescent assessment possible. That kind of longitudinal structure is hard to build and even harder to sustain. It allows investigators to move beyond a snapshot of exposure and outcome and examine whether a chemical burden measured during development still shadows the skeleton years later. The answer from this dataset is yes, at least for some PFAS and some skeletal outcomes.
The public health implications are concrete. PFAS are widespread, long-lived, and difficult to avoid through individual choice alone. Bone health also has a long fuse; the consequence of a smaller peak bone mass may not appear until adulthood, when fractures or premature bone loss begin to matter clinically. Intervening only after the skeleton has already failed misses the developmental window when prevention is most plausible.
The Remaining Gaps Are About Specificity, Not Direction
What remains unsettled is not whether PFAS deserve concern, but which compounds, which windows, and which hosts are most vulnerable. Associations differed by age at measurement, by skeletal site, and by sex, so a single blanket interpretation would be too crude. The cohort is also relatively small, which limits fine-grained subgroup analysis and leaves open the possibility that some findings will sharpen or soften with larger samples. Even so, the direction of travel is consistent with a broader endocrine toxicology literature: persistent chemical exposures during growth can alter the body’s long-term set points, and the skeleton appears to be one of the systems most exposed to that risk.